

Early and effective treatment of endometriosis can improve fertility.


EndomiR is an miRNA-based blood test for endometriosis. Through patented biomarkers, **EndomiR** has the ability to provide accurate results and drive clinical decisions.

91.0%*
Sensitivity

96.0%*
Specificity

*when compared with laparoscopic controls based on circulating levels of miRNAs in Afynia Laboratories' diagnostic panel **EndomiR**.

How It Works



Cost Effective

Less expensive than alternatives



Accurate

Equivalent to laparoscopy



Fast

Results delivered within days



Reliable

Clinically validated PCR technology

EndomiR is a laboratory developed test blood test manufactured by Afynia Laboratories and is intended to aid clinical providers in their diagnosis of endometriosis. *EndomiR* uses quantitative detection of circulating endometriosis-associated DNA regulatory markers in human plasma. A positive test result may indicate the presence of endometriosis. *EndomiR* is not a replacement for ultrasound imaging or diagnostic surgery in high-risk individuals. *EndomiR* is not for high-risk individuals, including patients with a personal history of endometriosis, history of ovarian cancer, or a positive result from another endometriosis screening method within the last 3 months. Positive *EndomiR* results should be referred to a gynecologist for follow up care. A negative *EndomiR* test result does not guarantee absence of endometriosis and patients should consult their physician. *EndomiR* performance when used for repeat testing has not been evaluated or established. *EndomiR* is available through physicians only.